Choksi Laborator

Which are the latest news on Choksi Laborator?

Why is Choksi Laboratories Ltd falling/rising?

As of 05-Sep, Choksi Laboratories Ltd's stock price is currently at 165.25, reflecting a decrease of 1.15 (-0.69%). Despite the short-term decline, the stock has shown strong performance with significant gains over the past week and month, indicating a generally favorable position overall.

As of 05-Sep, Choksi Laboratories Ltd's stock price is currently at 165.25, reflecting a decrease of 1.15 (-0.69%). Despite this decline, the stock has shown strong performance over various time frames, with a notable increase of 11.77% over the past week and 34.84% over the past month, significantly outperforming the Sensex, which has decreased by 0.97% and 2.44% respectively in the same periods. <BR><BR>Today, the stock opened with a gain of 4.45% and reached an intraday high of Rs 173.8. However, it also experienced a drop to an intraday low of Rs 163, indicating volatility within the trading day. The weighted average price suggests that more volume was traded closer to the low price, which may have contributed to the overall decline in the stock price. <BR><BR>Additionally, while the stock has fallen today, it has been trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend prior to this drop. The rising investor participation, with a delivery volume increase of 16.27% against the 5-day average, suggests continued interest in the stock, despite the current price decline. <BR><BR>In summary, while Choksi Laboratories Ltd is experiencing a short-term decline, its recent strong performance and positive trading indicators suggest that the stock remains in a favorable position overall.

Who are in the management team of Choksi Laborator?

The management team of Choksi Laborator includes Sunil Choksi (Managing Director & CEO), Stela Choksi, Vyangesh Choksi (CFO), Himika Choksi (Whole-time Directors), and several independent directors: Sudarshan Shastri, N K Mani, Raghmendra Singh, and Meenaxi Patidar, along with Prakhar Dubey as Company Secretary & Compliance Officer.

The management team of Choksi Laborator includes the following individuals:<BR><BR>1. **Sunil Choksi** - Managing Director & CEO<BR>2. **Stela Choksi** - Whole-time Director<BR>3. **Vyangesh Choksi** - Whole Time Director & CFO<BR>4. **Himika Choksi** - Whole-time Director<BR>5. **Sudarshan Shastri** - Independent Director<BR>6. **N K Mani** - Independent Director<BR>7. **Raghmendra Singh** - Independent Director<BR>8. **Meenaxi Patidar** - Independent Director<BR>9. **Prakhar Dubey** - Company Secretary & Compliance Officer<BR><BR>This team brings a mix of leadership and independent oversight to the company.

What does Choksi Laborator do?

Choksi Laboratories Ltd offers contract testing and analytical services in the healthcare sector and has a market cap of INR 98 Cr. As of June 2026, it reported net sales of 12 Cr and a net profit of 1 Cr.

Overview: <BR>Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Choksi Laboratories Ltd was incorporated on 29 January 1993. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 12 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 98 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 53.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.20 <BR>Return on Equity: 7.43% <BR>Price to Book: 4.04<BR><BR>Contact Details: <BR>Address: Survey no 9/1 Gram Kumerdi, Near to Tulshiyana Indl Park Indore Madhya Pradesh : 452010 <BR>Email: compliance_officer@choksi.com <BR>Website: http://www.choksilab.com

Who are the peers of the Choksi Laborator?

Choksi Laborator's peers include Bilcare, Jeevan Scienti., Star Imaging, Aspira Pathlab, Royal Sense, and Aakaar Medical. Choksi has a Good growth rating and a 1-year return of -27.89%, higher than Royal Sense but lower than its other peers.

Peers: The peers of Choksi Laborator are Bilcare, Jeevan Scienti., Star Imaging, Aspira Pathlab, Royal Sense, and Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense, Aakaar Medical, and Star Imaging, while Below Average management risk is found at Bilcare, Jeevan Scienti., Aspira Pathlab, and Choksi Laborator. Growth is classified as Excellent at Royal Sense, Good at Choksi Laborator and Bilcare, and Below Average at Jeevan Scienti., Aspira Pathlab, and Star Imaging. Capital Structure ratings show Excellent at Star Imaging, Good at Royal Sense and Aakaar Medical, Average at Aspira Pathlab, and Below Average at Bilcare, Jeevan Scienti., and Choksi Laborator.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jeevan Scienti. at 87.30%, while the lowest is Royal Sense at -62.36%. Choksi Laborator's 1-year return is -27.89%, which is higher than Royal Sense but lower than the other peers. Additionally, the six-month return is negative for Royal Sense and Modern Diagnost.

How big is Choksi Laborator?

As of 31st August, Choksi Laboratories Ltd has a market capitalization of 98.00 Cr, with recent net sales of 46.82 Cr and a net profit of 2.16 Cr. The latest balance sheet shows shareholder's funds of 25.58 Cr and total assets of 71.67 Cr.

As of 31st August, Choksi Laboratories Ltd has a market capitalization of 98.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Choksi Laboratories reported Net Sales of 46.82 Cr and a Net Profit of 2.16 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, showing Shareholder's Funds of 25.58 Cr and Total Assets of 71.67 Cr.

Should I buy, sell or hold Choksi Laboratories Ltd?

When is the next results date for Choksi Laboratories Ltd?

The next results date for Choksi Laboratories Ltd is August 13, 2026.

The next results date for Choksi Laboratories Ltd is scheduled for August 13, 2026.

Are Choksi Laboratories Ltd latest results good or bad?

Choksi Laboratories Ltd's latest Q4 FY26 results show a significant net profit increase of 232.26% and revenue growth of 12.46%, but concerns remain due to low return on equity (6.50%) and a high debt-to-EBITDA ratio (4.91), indicating underlying financial weaknesses. Overall, while there are positive signs, the results are mixed and warrant caution for investors.

Choksi Laboratories Ltd's latest results for Q4 FY26 show a mixed picture. On the positive side, the company reported a net profit of ₹1.03 crores, which is a significant increase of 232.26% compared to the previous quarter. Additionally, revenue grew by 12.46% year-on-year, reaching ₹12.82 crores, and the operating margin improved to 28.39%, up from 24.49% in the previous quarter.<BR><BR>However, there are notable concerns. The return on equity (ROE) remains low at 6.50%, indicating weak capital efficiency. The company also has a high debt-to-EBITDA ratio of 4.91 times, which raises questions about its financial stability. Furthermore, while the quarterly results show improvement, the annual profit stagnated at ₹1.00 crore, unchanged from the previous year, suggesting challenges in translating revenue growth into meaningful profit expansion.<BR><BR>In summary, while there are positive signs in the recent quarterly performance, underlying structural weaknesses and high leverage indicate that the overall results are not entirely favorable. Investors should weigh these factors carefully.

How has been the historical performance of Choksi Laborator?

Choksi Laborator has experienced growth in net sales and operating income from Mar'21 to Mar'25, but its profitability metrics, including profit before and after tax, have fluctuated significantly. The company needs to focus on cost management and operational efficiency despite improved cash flow from operating activities.

Answer:<BR>The historical performance of Choksi Laborator shows a mixed trend over the years, with notable fluctuations in revenue and profitability.<BR><BR>Breakdown:<BR>Choksi Laborator's net sales have shown a consistent upward trajectory, increasing from 25.69 Cr in Mar'21 to 41.78 Cr in Mar'25. Total operating income followed a similar pattern, rising from 28.49 Cr in Mar'20 to 41.78 Cr in Mar'25. The company's operating profit (PBDIT) has also improved, reaching 11.30 Cr in Mar'25 from 3.17 Cr in Mar'20, although the operating profit margin has slightly decreased from 29.73% in Mar'23 to 26.88% in Mar'25. Profit before tax fluctuated significantly, peaking at 3.72 Cr in Mar'23 before dropping to 2.15 Cr in Mar'25. Profit after tax also saw a decline from 3.21 Cr in Mar'23 to 1.52 Cr in Mar'25. The company's total liabilities increased from 59.49 Cr in Mar'23 to 64.79 Cr in Mar'25, while total assets rose from 59.49 Cr to 64.79 Cr in the same period. Cash flow from operating activities improved to 11.00 Cr in Mar'25, maintaining stability compared to previous years. Overall, while Choksi Laborator has shown growth in sales and operating income, its profitability metrics have experienced volatility, indicating a need for strategic focus on cost management and operational efficiency.

Is Choksi Laborator overvalued or undervalued?

As of October 13, 2025, Choksi Laborator is rated attractive but considered overvalued with high valuation ratios, including a PE of 85.25, despite strong stock performance, especially when compared to peers like Apollo Hospitals and Max Healthcare.

As of 13 October 2025, the valuation grade for Choksi Laborator has moved from very attractive to attractive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 85.25, while the Price to Book Value is 5.42, and the EV to EBIT is 33.62, all indicating a premium valuation compared to its peers.<BR><BR>In comparison, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.2 and an EV to EBITDA of 36.12. Max Healthcare, rated as very expensive, has a PE ratio of 92.33, but its high valuation does not justify the premium over Choksi Laborator. Despite Choksi's impressive stock performance, with a year-to-date return of 144.57% compared to the Sensex's 5.36%, the elevated valuation ratios suggest that the stock may be overvalued in the current market environment.

Who are the top shareholders of the Choksi Laborator?

The top shareholders of Choksi Laborator include promoter Sunil Choksi with 7.51% and public shareholder Sachin Seth with 3.96%. Individual investors hold 52.67%, while foreign institutional investors own 1.94%, and there are no mutual funds invested in the company.

The top shareholders of Choksi Laborator include Sunil Choksi, who is the promoter with the highest holding at 7.51%. Following him, Sachin Seth is the highest public shareholder with a stake of 3.96%. Additionally, individual investors collectively hold a significant portion of the company at 52.67%. The company also has 1.94% held by foreign institutional investors (FIIs), but there are no mutual funds currently invested in it.

What is the technical trend for Choksi Laborator?

As of June 3, 2025, Choksi Laborator's technical trend has shifted to bullish, supported by strong daily moving averages and monthly indicators, despite some mildly bearish signals on the weekly MACD and KST.

As of 3 June 2025, the technical trend for Choksi Laborator has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands confirm a bullish trend. Despite the weekly MACD and KST showing mildly bearish signals, the monthly MACD and KST are bullish, reinforcing the overall positive outlook. Dow Theory also indicates a bullish trend on both weekly and monthly time frames. The stock has shown significant returns compared to the Sensex, further highlighting its strength in the market.

Has Choksi Laborator declared dividend?

No Dividend History Available